PF-Atlas › Clinical Trials › NCT04362761

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

ELX/TEZ/IVA · Phase 3

Registry ID
NCT04362761
Phase
Phase 3
Status
Completed
Drug / intervention
ELX/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2020-05-04
Enrollment
172
Locations
29

About this trial

This study evaluate the long-term safety and tolerability of elexacaftor (ELX)/tezacaftor (TEZ)/ ivacaftor (IVA) triple combination (TC) in participants with cystic fibrosis (CF) who are homozygous for F508del.

View NCT04362761 on ClinicalTrials.gov →

Explore related

All ELX/TEZ/IVA trialsAll IPF trials

Related trials

ELX/TEZ/IVA — NCT05153317ELX/TEZ/IVA — NCT04545515ELX/TEZ/IVA — NCT05274269ELX/TEZ/IVA — NCT03691779ELX/TEZ/IVA — NCT04702360ELX/TEZ/IVA — NCT04105972
Medical disclaimer. This page summarizes public trial data for NCT04362761 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.